Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)Locally AdvancedUnresectable

Interventions

DEVICE

Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas

YntraDose™ is a locoregional therapy device used for percutaneous radio-ablation of solid tumours